Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
Do you use lenalidomide for patients with MDS with 5q- without other cytogenetic abnormalities but with one or more mutations on NGS?
Are there certain mutations that would lead you to avoid use of lenalidomide, for example TP53?
Related Questions
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
How do you sequence luspatercept and imetelstat for treatment of anemia in MDS?
How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?
How do you approach imetelstat therapy in MDS patients with baseline neutropenia or thrombocytopenia?
Do you routinely include bone marrow examination in your initial evaluation of a patient with chronic myeloid leukemia?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
Is obinutuzumab obligatory with AV combination for patients with unmutated IGHV?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?